https://scholars.lib.ntu.edu.tw/handle/123456789/580282
標題: | Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma | 作者: | YU-YUN SHAO PEI-JER CHEN ZHONG-ZHE LIN Huang C.-C. Ding Y.-H. Lee Y.-H. CHIH-HUNG HSU ANN-LII CHENG |
公開日期: | 2011 | 出版社: | International Institute of Anticancer Research | 卷: | 31 | 期: | 11 | 起(迄)頁: | 4007-4011 | 來源出版物: | Anticancer Research | 摘要: | Background: Hepatitis B virus (HBV) infection is one of the main etiologies of hepatocellular carcinoma (HCC). We explored the impact of HBV DNA levels on the prognosis of patients with advanced HCC. Patients and Methods: The study was based on patients with advanced HCC and chronic HBV infection enrolled into three phase II trials evaluating first-line antiangiogenic therapy. Pretreatment HBV DNA levels were measured by real-time quantitative polymerase chain reaction. Results: Seventy-two patients were included. Patients with detectable HBV DNA levels had poorer median overall survival (OS) compared to patients without detectable levels (4.8 vs. 9.3 months, p=0.037). After adjusting for other clinicopathologic variables, the baseline HBV DNA level was an independent predictor of poor OS (p=0.014). Baseline HBV DNA levels were not correlated with progression-free survival or disease control rate. Conclusion: Baseline HBV DNA levels were associated with the prognosis of patients with chronic HBV infection receiving antiangiogenic therapy for advanced HCC. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984552696&partnerID=40&md5=87f850e929995ee0e43001e6c269c960 https://scholars.lib.ntu.edu.tw/handle/123456789/580282 |
SDG/關鍵字: | angiogenesis inhibitor; bevacizumab; capecitabine; sorafenib; thalidomide; UFT; virus DNA; adult; advanced cancer; aged; antiangiogenic therapy; article; blood sampling; cancer combination chemotherapy; cancer patient; clinical assessment; controlled study; disease control; female; hepatitis B; Hepatitis B virus; human; liver cell carcinoma; major clinical study; male; multiple cycle treatment; overall survival; pathophysiology; phase 2 clinical trial; priority journal; prognosis; progression free survival; quantitative analysis; real time polymerase chain reaction; risk factor; treatment outcome; treatment response; virus detection |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。